Reenie McCarthy is the Chief Executive Officer, President and a member of the Board of Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational therapies to treat diseases of mitochondrial dysfunction including diseases of aging. Reenie previously led the US-based investment team of Morningside Ventures from 1993 through 2015, providing operational and Board-level management oversight to venture- and private-equity backed companies in the United States, Canada, Europe and China. Reenie is a member of the Board of Directors of Biotechnology Innovation Organization. Reenie earned her J.D. from the University of Pennsylvania Carey School of Law and her B.A. from Bates College.